{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:00:36Z","timestamp":1791489636699,"version":"4.3.4"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":246,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004160","name":"Mazandaran University of Medical Sciences","doi-asserted-by":"publisher","award":["Project No. 3500"],"award-info":[{"award-number":["Project No. 3500"]}],"id":[{"id":"10.13039\/501100004160","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101431","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T20:48:12Z","timestamp":1788814092000},"page":"101431","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["In vitro functional evaluation of soluble single domain antibodies targeting the HER2 dimerization domain"],"prefix":"10.1016","volume":"49","author":[{"given":"Mahdieh","family":"Darvish-Khezri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza Eshaghi","family":"Gorji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeid","family":"Taghiloo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Tehrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abolghasem","family":"Ajami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehsan","family":"Zaboli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atefeh Habibi","family":"Asl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9074-6994","authenticated-orcid":false,"given":"Reza","family":"Valadan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ctarc.2026.101431_bib0001","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1186\/s13046-022-02515-x","article-title":"HER3 in cancer: from the bench to the bedside","volume":"41","author":"Gandullo-S\u00e1nchez","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101431_bib0002","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.3390\/cancers15041069","article-title":"Immunotherapies against HER2-positive breast cancer","volume":"15","author":"Duro-S\u00e1nchez","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctarc.2026.101431_bib0003","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0959-8049(01)00230-1","article-title":"The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities","volume":"37","author":"Yarden","year":"2001","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ctarc.2026.101431_bib0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/bcr327","article-title":"Intracellular signaling pathways of ErbB2\/HER-2 and family members","volume":"3","author":"Olayioye","year":"2001","journal-title":"Breast Cancer Res."},{"issue":"7","key":"10.1016\/j.ctarc.2026.101431_bib0005","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nrm1962","article-title":"EGF\u2013ERBB signalling: towards the systems level","volume":"7","author":"Citri","year":"2006","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101431_bib0006","article-title":"Association of HER1 and HER2 gene variants in the predisposition of colorectal cancer","volume":"2021","author":"Alanazi","year":"2021","journal-title":"J. Oncol."},{"issue":"11","key":"10.1016\/j.ctarc.2026.101431_bib0007","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.3390\/genes13112065","article-title":"Antibody-drug conjugates for the treatment of HER2-positive breast cancer","volume":"13","author":"Najjar","year":"2022","journal-title":"Genes (Basel)"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101431_bib0008","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1080\/13543784.2021.1854724","article-title":"Experimental HER2-targeted therapies for biliary tract cancer","volume":"30","author":"Rizzo","year":"2021","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"10","key":"10.1016\/j.ctarc.2026.101431_bib0009","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.3390\/cancers14102569","article-title":"Breast cancer\u2014epidemiology, classification, pathogenesis and treatment (review of literature)","volume":"14","author":"Smolarz","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.ctarc.2026.101431_bib0010","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/ncponc0509","article-title":"Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer","volume":"3","author":"Nahta","year":"2006","journal-title":"Nat. Clin. Pract. Oncol."},{"issue":"10","key":"10.1016\/j.ctarc.2026.101431_bib0011","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1073\/pnas.89.10.4285","article-title":"Humanization of an anti-p185HER2 antibody for human cancer therapy","volume":"89","author":"Carter","year":"1992","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101431_bib0012","first-page":"391","article-title":"Pertuzumab in metastatic breast cancer","volume":"3","author":"Patel","year":"2012","journal-title":"J. Adv. Pr. Oncol."},{"key":"10.1016\/j.ctarc.2026.101431_bib0013","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3389\/fonc.2012.00062","article-title":"Trastuzumab: updated mechanisms of action and resistance in breast cancer","volume":"2","author":"Vu","year":"2012","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101431_bib0014","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.clbc.2011.07.001","article-title":"Blockade of the HER family of receptors in the treatment of HER2-positive metastatic breast cancer","volume":"12","author":"Sachdev","year":"2012","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.ctarc.2026.101431_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13058-019-1127-y","article-title":"Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer","volume":"21","author":"Kennedy","year":"2019","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101431_bib0016","first-page":"65","article-title":"Role of pertuzumab in the treatment of HER2-positive breast cancer","author":"Hubalek","year":"2012","journal-title":"Breast Cancer: Targets Ther."},{"issue":"7","key":"10.1016\/j.ctarc.2026.101431_bib0017","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.3390\/cancers13071664","article-title":"Novel HER2-directed treatments in advanced gastric carcinoma: anotHER paradigm shift?","volume":"13","author":"Ricci","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctarc.2026.101431_bib0018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12935-021-02182-6","article-title":"Recombinant immunotoxins development for HER2-based targeted cancer therapies","volume":"21","author":"Mahmoudi","year":"2021","journal-title":"Cancer Cell Int."},{"issue":"10","key":"10.1016\/j.ctarc.2026.101431_bib0019","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.yexcr.2012.03.004","article-title":"Targeting high affinity and epitope-distinct oligoclonal nanobodies to HER2 over-expressing tumor cells","volume":"318","author":"Jamnani","year":"2012","journal-title":"Exp. Cell Res."},{"issue":"44","key":"10.1016\/j.ctarc.2026.101431_bib0020","doi-asserted-by":"crossref","first-page":"17121","DOI":"10.1073\/pnas.0805297105","article-title":"Human domain antibodies to conserved sterically restricted regions on gp120 as exceptionally potent cross-reactive HIV-1 neutralizers","volume":"105","author":"Chen","year":"2008","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ctarc.2026.101431_bib0021","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/9783527682423.ch19","article-title":"Engineered antibody domains as candidate therapeutics","author":"Chen","year":"2014","journal-title":"Handb. Ther. Antibodies"},{"key":"10.1016\/j.ctarc.2026.101431_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110999","article-title":"Single domain antibodies specific for HER2 dimerization domain effectively disrupts HER2 dimerization","volume":"124","author":"Najafi","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.ctarc.2026.101431_bib0023","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.3389\/fmicb.2017.02169","article-title":"Revisiting the mechanisms involved in calcium chloride induced bacterial transformation","volume":"8","author":"Asif","year":"2017","journal-title":"Front. Microbiol."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101431_bib0024","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1002\/jcp.29216","article-title":"Overcoming trastuzumab resistance in HER2-positive breast cancer using combination therapy","volume":"235","author":"Derakhshani","year":"2020","journal-title":"J. Cell. Physiol."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101431_bib0025","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jconrel.2010.04.009","article-title":"The role of HER2 in cancer therapy and targeted drug delivery","volume":"146","author":"Tai","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ctarc.2026.101431_bib0026","article-title":"Suppression of breast cancer cell proliferation by selective single-domain antibody for intracellular STAT3","volume":"12","author":"Singh","year":"2018","journal-title":"Breast Cancer: Basic Clin. Res."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101431_bib0027","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3109\/1040841X.2016.1150959","article-title":"Microbial platform technology for recombinant antibody fragment production: a review","volume":"43","author":"Gupta","year":"2017","journal-title":"Crit. Rev. Microbiol."},{"key":"10.1016\/j.ctarc.2026.101431_bib0028","article-title":"A novel nanobody-based HER2-targeting antibody exhibits potent synergistic antitumor efficacy in trastuzumab-resistant cancer cells","volume":"14","author":"Liu","year":"2023","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.ctarc.2026.101431_bib0029","doi-asserted-by":"crossref","first-page":"7887","DOI":"10.1007\/s13277-014-1854-8","article-title":"Triple blockade of HER2 by a cocktail of anti-HER2 scFv antibodies induces high antiproliferative effects in breast cancer cells","volume":"35","author":"Nejatollahi","year":"2014","journal-title":"Tumor Biol."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101431_bib0030","first-page":"180","article-title":"Anti-proliferative effect of specific anti-EGFR single chain antibody on triple negative breast cancer cells","volume":"9","author":"Abdollahzadeh","year":"2020","journal-title":"Rep. Biochem. Mol. Biol."},{"issue":"47","key":"10.1016\/j.ctarc.2026.101431_bib0031","doi-asserted-by":"crossref","first-page":"82872","DOI":"10.18632\/oncotarget.19958","article-title":"Anti-proliferative and pro-apoptotic effects induced by simultaneous inactivation of HER1 and HER2 through endogenous polyclonal antibodies","volume":"8","author":"Su\u00e1rez","year":"2017","journal-title":"Oncotarget"},{"issue":"22","key":"10.1016\/j.ctarc.2026.101431_bib0032","first-page":"5107","article-title":"Synergistic inhibition of growth and induction of apoptosis by 8-chloro-cAMP and paclitaxel or cisplatin in human cancer cells","volume":"57","author":"Tortora","year":"1997","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101431_bib0033","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/00000478-199701000-00010","volume":"21","author":"Cummings","year":"1997","journal-title":"Am. J. Surg. Pathol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101431_bib0034","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1756-9966-29-23","article-title":"Anti-HER-2 engineering antibody ChA21 inhibits growth and induces apoptosis of SK-OV-3 cells","volume":"29","author":"Zhang","year":"2010","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101431_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.pep.2024.106649","article-title":"Production and functional analysis of a phage displayed scFv recombinant antibody targeting EGFR\/HER2 dimerization domain","volume":"228","author":"Dabiri","year":"2025","journal-title":"Protein Expr. Purif."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226003412?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226003412?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:43:01Z","timestamp":1791488581000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226003412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":35,"alternative-id":["S2468294226003412"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101431","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro functional evaluation of soluble single domain antibodies targeting the HER2 dimerization domain","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101431","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101431"}}